title: Treatment of severe snoring with a combination of pseudoephedrine sulfate and domperidone.
abstract: OBJECTIVE
  Pharmacologic treatment of severe snoring has not been considered to be of great value. The objective of this study was to determine whether the combination of a nasal decongestant and a prokinetic drug would decrease or eliminate severe snoring.
  
  
  METHODS
  Thirty healthy individuals whose sleeping partners reported that the patients had severe nightly snoring entered an open-label trial of 60 mg of pseudoephedrine and 10 mg of domperidone at bedtime for 30 days. Each night's snoring was scored on a diary by the sleeping partner. At the end of the open-label trial, a subset of subjects whose snoring had recurred were randomized to one or both placebo-controlled trials, either 60 mg of pseudoephedrine sulfate plus 10 mg of domperidone or to 30 mg of pseudoephedrine sulfate plus 10 mg of domperidone. In another placebo-controlled trial, the drug combination was compared with each component.
  
  
  RESULTS
  In the open-label trial, 493 of 772 evaluable subject-nights were free of snoring; another 232 nights were scored as mild snoring. In the placebo-controlled trials, low-dose therapy caused a reduction in snoring, and high-dose therapy even a greater reduction in snoring. The drug combination was more effective than either agent alone.
  
  
  CONCLUSIONS
  Treatment with a prokinetic agent plus a nasal decongestant reduced or eliminated severe snoring in the majority of subjects treated.
authors.affiliation: Clinica Servet, Santiago, Chile.
authors.forename: Augusto
authors.initials: A
authors.lastname: Larrain
authors.forename: Monica
authors.initials: M
authors.lastname: Hudson
authors.forename: Jason A
authors.initials: JA
authors.lastname: Dominitz
authors.forename: Charles E
authors.initials: CE
authors.lastname: Pope
mesh_terms: D000328:Adult; D004294:Domperidone / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D004809:Ephedrine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D012720:Severity of Illness Index; D012913:Snoring / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D018492:Dopamine Antagonists; D014662:Vasoconstrictor Agents; D004294:Domperidone; D004809:Ephedrine